Skip to main content

Table 3 Summary of studies reporting assessment of EGFR/KRAS or EGFR/KRAS/other molecular markers

From: Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

Reference

Patient demographics:

Description of matched pairs

Synchronous/metachronous/metastases, n:n

Molecular marker assessment technique

Mutation frequency,c n/N (%)

Concordance, n/N (%)

(i) Median age (range), years

N

Tumour sample storage form

Primary

Metastatic: n

 

(ii) Gender, n/N (%) male

Histological subtype: n

Time between primary and metastatic tumour sample collection b

(iii) Ethnicity [countrya]

 

(iv) Smoking status, n/N (%)

Assessment of EGFR/KRAS molecular markers

 Han et al. [49]

(i) 60 (44–76)

22

Snap frozen

Lung

Lymph node

N/A

Direct sequencing

[EGFR]

[EGFR]

(ii) 12/22 (55)

ADC: 15

N/A

7/22 (32) vs 6/22 (27)

21/22 (95)

(iii) [China]

SSC: 7

[KRAS]

[KRAS]

(iv) Never-smoker: 6/22 (27); former smoker: 5/22 (23); current smoker: 11/22 (50)

2/22 (9) vs 1/22 (5)

21/22 (95)

 Han et al. [29]

(i) 66 (40–94)

37

FFPE

Lung

Pleural effusion: 12

32:5

Direct sequencing

[EGFR]

[EGFR]

(ii) 20/37 (54.1)

ADC: 37

Pleura: 9

N/A

 

18/37 (49) vs 16/37 (43)

30/37 (81)

(iii) [Korea]

Brain: 5

[KRAS]

[KRAS]

(iv) Never-smoker: 18/37 (48.6); former and current smoker: 16/37 (43.2)

Lymph node: 3

1/37 (3) vs 2/37 (5)

36/37 (97)

Lung: 2

Soft tissue: 2

Adrenal gland: 1

Pericardial effusion: 1

Pericardium: 1

Ovary: 1

 Kalikaki et al. [46]

(i) 55 (41–70)

25

FFPE

Lung

Lung: 9

0:25

Direct sequencing

[EGFR]

[EGFR]

(ii) 22/25 (88)

ADC: 18

Thoracic wall: 5

Median time between resection of primary and corresponding metastatic tumours: 30 months (range 4–143)

5/25 (20) vs 3/25 (12)

18/25 (72)

(iii) Caucasian

SSC: 2

Adrenal gland: 4

[KRAS]

[KRAS]

(iv) Never-smoker: 3/25 (12); active or former smoker: 22/25 (88)

ADC/BAC: 2

Brain: 3

5/25 (20) vs 5/25 (20)

19/25 (76)

LCC: 2

Bone: 2

GCC: 1

Skin: 1

Liver: 1

 Munfus-McCray et al. [48]

(i) 56.3 (51–80)

9

FFPE

Lung

Brain: 3

N/A

[EGFR] Bidirectional DNA sequencing

[EGFR]

[EGFR]

(ii) N/A (66.7)

Lymph node: 3

N/A

[KRAS] Pyrosequencing following microdissection of tumour tissue

3/9 (33) vs 2/9 (22)

8/9 (89)

(iii) [USA]

Pleura: 1

[KRAS]

[KRAS]

(iv) Never-smoker: 4/9 (N/A); current and former smoker: 4/9 (N/A)

Knee: 1

1/9 (11) vs 2/9 (22)

8/9 (89)

Contralateral lung: 1

 Sun et al. [32]

(i) [Mean] 58 (32–77)

80

FFPE

Lung

Lymph nodes

80:0

Direct sequencing

[EGFR]

[EGFR]

(ii) 50/80 (62.5)

ADC: 39

[Concurrent]

21/80 (26) vs 26/80 (33)

73/80 (91)

(iii) Chinese

SSC: 31

[KRAS]

[KRAS]

(iv) Never-smoker: 31/80 (38.75); ever-smoker: 49/80 (61.25)

Adenosquamous carcinoma: 6

1/80 (1) vs 7/80 (9)

74/80 (93)

LCC: 4

Assessment of EGFR/KRAS/BRAF molecular markers

 Schmid et al. [47]

(i) 62 (42–81)

96

FFPE

Lung

Locoregional lymph node

N/A

Direct bidirectional sequencing

[EGFR]

[EGFR]

(ii) 58/96 (60.4)

N/A

4/96 (4) vs 4/96 (4)

90/96 (94)

(iii) Caucasian [Austria]

[KRAS]

[KRAS]

(iv) Never-smoker: 22/96 (23); current smoker: 60/96 (63); former smoker: 14/96 (15)

28/96 (29) vs 20/96 (21)

71/96 (74)

[BRAF]

[BRAF]

2/96 (2) vs 0/96 (0)

94/96 (98)

Assessment of EGFR/KRAS/p53 molecular markers

 Takahashi et al. [61]

(i) [At diagnosis] (43–79)

8

FFPE

Lung

Brain: 7

N/A

High resolution SNP array (following laser capture microdissection in some cases)

[EGFR]

N/A

(ii) 5

ADC: 3

Lymph node: 3

Time between resection of primary and corresponding metastatic tumours (range): 0–64 months (not reported for 2 sample pairs)

3/8 (38) vs 3/8 (38)

(iii) [Japan]

SSC: 1

Liver: 2

[p53]

(iv) Never-smoker: 3; ever-smoker: 5

LCC: 1

Pulmonary: 1

7/8 (88) vs 7/8 (88)

SCC: 3

Pleural: 1

[KRAS]

0/8 (0) vs 0/8 (0)

  1. ADC Adenocarcinoma, BAC Bronchioloalveolar carcinoma, BRAF Murine sarcoma viral oncogene homolog B1, DNA Deoxyribonucleic acid, EGFR Epidermal growth factor receptor, FFPE Formalin-fixed paraffin-embedded, GCC Giant cell carcinoma, KRAS Kirsten rat sarcoma viral oncogenes homolog, LCC Large cell carcinoma, N/A Not available, SCC Small cell carcinoma, SNP Single nucleotide polymorphism, SSC Squamous cell carcinoma
  2. aAs described in study (country from which samples were taken from)
  3. bConcurrent or non-concurrent if time not specified
  4. cPrimary vs metastatic tumour samples
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us